While known for weight loss, GLP-1 agonists are also highly effective for managing hyperglycemia from both steroids and PI3K inhibitors. Using low or "micro" doses can be very helpful in cancer patients, providing glucose control while minimizing GI side effects like nausea.

A novel pilot study, the TRIMM trial, is investigating if a GLP-1 agonist can eliminate minimal residual disease (MRD), as measured by ctDNA, in breast cancer patients with obesity. This frames a metabolic intervention as a potential anti-cancer therapeutic, moving beyond its role in supportive care.

To prevent rebound weight gain and associated inflammation—which is particularly detrimental for cancer survivors—patients should not stop GLP-1s abruptly. Instead, a slow, methodical 20-week taper is recommended, with close monitoring to ensure weight stability before full discontinuation.

Early retrospective data from major cancer centers suggests patients on hormone therapy experience less weight loss with GLP-1 agonists. This indicates a potential drug interaction that may require clinicians to more closely monitor weight trends and consider dose adjustments for this patient population.

GLP-1s are more than weight-loss aids; they are powerful anti-inflammatory agents affecting cardiovascular and neurological health. They even reduce cravings for things like gambling and cigarettes, acting as systemic moderators for entire biological systems, not just appetite.

Unpublished data from a UT Southwestern group indicates that using GLP-1 agonists during a specific neoadjuvant chemo-immunotherapy regimen (Keynote 522) may significantly reduce pathologic complete response rates. This critical safety concern is prompting forthcoming ESMO guidelines recommending against their concurrent use.

The obesity market is evolving beyond maximum weight loss. Key differentiators will become dosing convenience, side effect profiles, and preserving lean muscle. This creates space for novel mechanisms, potentially as add-on therapies to lower GLP-1 doses and mitigate side effects.

GLP-1 drugs cause a precipitous drop in inflammation markers within weeks, much faster than the timeline for weight loss. This independent anti-inflammatory mechanism may explain their efficacy in conditions like knee pain and psoriasis.

Unlike most drugs with targeted effects, GLP-1s are remarkable for their broad-based impact. They concurrently improve metabolism, mitochondrial creation, cellular cleanup (autophagy), and inflammation, explaining their profound and varied benefits.